evidencegaps
Primary study · included by 1 review

Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab.

Kasahara 2024 · Kasahara Yuki, Saijo Ken, Ueta Reio, et al. · Scientific reports · 2024

Included by

Prognostic Significance of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Tumor-Associated Neutrophils in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
Non-Cochrane · prognostic · 2026 · cited as Kasahara 2024 · Table S3

The review does not say which of its outcomes this study informs.

1 including review in total.